Kudo M - Search Results

1

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.

Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, Tovoli F, Knox JJ, Ruth He A, El-Rayes BF, Acosta-Rivera M, Lim HY, Neely J, Shen Y, Wisniewski T, Anderson J, Hsu C. Yau T, et al. Among authors: kudo m. JAMA Oncol. 2020 Nov 1;6(11):e204564. doi: 10.1001/jamaoncol.2020.4564. Epub 2020 Nov 12. JAMA Oncol. 2020. PMID: 33001135 Free PMC article. Clinical Trial.

2

Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy.

Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, Tatsumi C, Ueda T, Minami Y, Ueshima K, Haji S. Takahashi S, et al. Among authors: kudo m. Oncology. 2007;72 Suppl 1:98-103. doi: 10.1159/000111714. Epub 2007 Dec 13. Oncology. 2007. PMID: 18087189

3

Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study.

Kudo M, Sakaguchi Y, Chung H, Hatanaka K, Hagiwara S, Ishikawa E, Takahashi S, Kitai S, Inoue T, Minami Y, Ueshima K. Kudo M, et al. Oncology. 2007;72 Suppl 1:132-8. doi: 10.1159/000111719. Epub 2007 Dec 13. Oncology. 2007. PMID: 18087194

4

Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy.

Kudo M. Kudo M. Oncology. 2008;75 Suppl 1:1-12. doi: 10.1159/000181865. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092266 Review.

5

Impact of interferon therapy after curative treatment of hepatocellular carcinoma.

Kudo M. Kudo M. Oncology. 2008;75 Suppl 1:30-41. doi: 10.1159/000173422. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092270

6

PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapy.

Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, Tatsumi C, Ueda T, Nagai T, Minami Y, Ueshima K. Takahashi S, et al. Among authors: kudo m. Oncology. 2008;75 Suppl 1:91-8. doi: 10.1159/000173429. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092277

7

Response evaluation of transcatheter arterial chemoembolization in hepatocellular carcinomas: the usefulness of sonazoid-enhanced harmonic sonography.

Xia Y, Kudo M, Minami Y, Hatanaka K, Ueshima K, Chung H, Hagiwara S, Inoue T, Ishikawa E, Kitai S, Takahashi S, Tatsumi C, Ueda T, Hayaishi S, Maekawa K. Xia Y, et al. Among authors: kudo m. Oncology. 2008;75 Suppl 1:99-105. doi: 10.1159/000173430. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092278

8

Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma.

Ueshima K, Kudo M, Nagai T, Tatsumi C, Ueda T, Takahashi S, Hatanaka K, Kitai S, Ishikawa E, Inoue T, Hagiwara S, Minami Y, Chung H. Ueshima K, et al. Among authors: kudo m. Oncology. 2008;75 Suppl 1:106-13. doi: 10.1159/000173431. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092279

9

Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice.

Kudo M. Kudo M. Int J Clin Oncol. 2010 Jun;15(3):242-55. doi: 10.1007/s10147-010-0089-y. Epub 2010 May 28. Int J Clin Oncol. 2010. PMID: 20509038 Review.

10

Management of hepatocellular carcinoma: from prevention to molecular targeted therapy.

Kudo M. Kudo M. Oncology. 2010 Jul;78 Suppl 1:1-6. doi: 10.1159/000315222. Epub 2010 Jul 8. Oncology. 2010. PMID: 20616576

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,540 results

Search Page

Filters